Sanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.
XNK Therapeutics AB has secured a private placement of €12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.
CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
TCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Bavarian Nordic is to receive up to US$225 and double-digit royalties for granting exclusive Chinese commercialisation rights for MVA-BN® RSV to Nuance Pharma.
Switzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.
Gilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.
With €80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals.
Sanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.